Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US.

The company plans to submit efsitora, its once-weekly insulin for type 2 diabetes, to global regulators by end-2026 following ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

Eli Lilly and Co. (LLY) announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa ...

In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand. In the trial, efsitora was titrated to four fixed doses at four-week ...